Centenara Labs Vascular Program
Asset
Slows down and reverses damage to brain vasculature.
- Stage
- Preclinical
- Modality
- Small molecule
- Target
- Not known
- 0
- Indications
- 0
- Trials
- 1
- Developer
Indications
1No named disease
Preclinical, centenara.com, 10 Oct 2026
In the full profile
- Owner and partners1
Every asset’s record: target, stage, trials and the evidence behind it.